Quetiapine fumarate, tablet, 25 mg, 100 mg, 200 mg and 300 mg (base), Seroquel, July 2007
Public summary document for Quetiapine fumarate, tablet, 25 mg, 100 mg, 200 mg and 300 mg (base), Seroquel, July 2007
Page last updated: 26 October 2007
PDF version of this page (PDF 42KB)
Public Summary Document
Product: Quetiapine fumarate, tablet, 25 mg, 100 mg, 200 mg and 300 mg (base), Seroquel
Sponsor: AstraZeneca Pty Ltd
Date of PBAC Consideration: July 2007
1. Purpose of Application
To extend the current authority required PBS listing for quetiapine to include the treatment, as monotherapy, of a patient with bipolar 1 disorder.
2. Background
Quetiapine has not previously been considered by the PBAC for treatment of bipolar 1 disorder.
3. Registration Status
Quetiapine was registered by the TGA on 31 March 2004 as monotherapy for the short-term
treatment of acute mania associated with Bipolar 1 Disorder.
Quetiapine is also registered for the treatment of schizophrenia.
4. Listing Requested and PBAC’s View
Authority required
As monotherapy for the treatment of bipolar 1 disorder
For PBAC’s view, see Recommendation and Reasons
5. Clinical Place for the Proposed Therapy
Bipolar disorder (BPD) (sometimes referred to as manic depression) is a medical condition
that affects the brain, causing extreme changes in mood. There are two types of BPD,
type 1 defined as having at least one manic episode, with or without depressive episodes,
and type two as defined by hypomania and depression.
The atypical antipsychotics are often used to treat patients with BPD. However, individual
response, both for efficacy and tolerability, is unpredictable.
Quetiapine is an atypical antipsychotic that will provide an alternative when used
as monotherapy to currently available drugs to treat BPD.
6. Comparator
The submission nominated olanzapine as the main comparator. The PBAC considered that
the choice of comparator is appropriate for establishing the clinical relativity of
quetiapine in bipolar I disorder.
However, for the purpose of establishing pricing relativities the PBAC considered
risperidone rather than olanzapine as the relevant comparator because risperidone
is listed for the treatment of acute episodes of bipolar 1 disorder, whereas olanzapine
is listed for the maintenance treatment of bipolar 1, a broader listing.
7. Clinical Trials
The submission presented as pivotal evidence a comparison of quetiapine and olanzapine
in bipolar 1 disorder based on data from two direct randomised, open label trials
in adult inpatients with bipolar acute mania or with bipolar affective disorder and
schizoaffective disorder, manic or mixed, and an indirect comparison containing four
randomised placebo controlled trials in adult inpatients or outpatients with a manic
or mixed episode.
The direct comparison trials had been published at the time of submission as follows:
Trial/First author |
Protocol title |
Publication citation |
---|---|---|
Belenkaya et al, 2005 |
Open comparative randomized study efficacy and tolerability of risperidone, olanzapine and quetiapine in acute mania. |
European Neuropsychopharmacology 2005; 15 (Suppl 2): S130 |
Ionescu et al, 2004 |
Efficacy and tolerability of quetiapine compared with olanzapine for inpatients with acute mania. |
European Psychiatry 2004; 19 (Suppl 1): 206S, Abs P26 |
The indirect comparison trials had been published at the time of submission as follows:
Trial ID |
Protocol title/ Publication title |
Publication citation |
---|---|---|
Quetiapine vs placebo |
||
AZ 104 |
Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double blind, randomised, parallel-group, placebo-controlled trial. |
European Neuropsychopharmacology; 15(5): 573 |
AZ 105 |
A randomized, double blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder |
The Journal of Clinical Psychiatry; 66(1): 111-121 |
Olanzapine vs placebo |
||
Tohen et al, 1999 |
Olanzapine versus placebo in the treatment of acute mania |
Am J Psychiatry; 156(6)702-9 |
Tohen et al, 2000 |
Efficacy of olanzapine in acute bipolar mania |
Arch Gen Psychiatry 2000; 57:841-849 |
8. Results of Trials
Comparative effectiveness
Direct Comparison
Percentage of responders at Week 6 (response defined as achieving > 50% reduction
in Young Mania Rating Scale (YMRS) score)
Trial |
Percentage of responders |
---|---|
Belenkaya et al, 2005 |
57% |
The percentage of responders trended towards higher levels in the quetiapine group
compared to the olanzapine group (67.8% vs 63.2%, respectively) however the statistical
significance of the difference was not reported.
Change from baseline in YMRS scores
Quetiapine |
Olanzapine |
Risperidone |
|||||||
---|---|---|---|---|---|---|---|---|---|
Baseline |
Day 42 |
Change |
Baseline |
Day 42 |
Change |
Baseline |
Day 42 |
Change |
|
Belenkaya et al, 2005 |
281.6 |
14.1 |
49.60% |
26.81.5 |
10.71.2 |
61.00% |
26.42.1 |
13.1 |
50.4% |
The percentage change in YMRS scores from baseline to endpoint favours the olanzapine
group over the quetiapine group (61% vs 50%, respectively) although the statistical
significance of the difference was not reported.
Ionescu et al, 2004 did not report any numerical results but stated that no significant
difference between quetiapine (n=16) and olanzapine (n=32) groups was found for any
efficacy variable (YMRS score and response rate, and PANSS, CGI-S, CGI-I, GAF scores).
Indirect comparison
The primary outcome in the quetiapine versus placebo studies included in the indirect
studies was the mean change from baseline to day 21 in YMRS score. Response rate (defined
as a ?50% decrease in YMRS score from baseline) was a secondary outcome. In the olanzapine
versus placebo studies, both the mean change in YMRS score from baseline and response
rate (?50% decrease in YMRS score from baseline) were primary outcomes.
The results of the indirect comparison with placebo as the common reference are reported
below.
Meta-analysis of mean change in YMRS total score from baseline, random effects model
Based on the provided results of the meta-analysis of mean change in YMRS total score
from baseline, random effects model, the combined estimate appeared to be similar
across the two sets of trials and suggested that patients on active treatment (quetiapine
or olanzapine) achieved a statistically significant greater mean improvement in YMRS
total score than patients on placebo.
Meta-analysis of YMRS response (decrease of ?50% from baseline in YMRS total score)
at Day 21, random effects model
The results appear to suggest that although both sets of trials showed that active
treatment resulted in better clinical response compared to placebo at Day 21, the
clinical response in the olanzapine-treated patients was statistically significant
with a narrower confidence interval and no evidence of heterogeneity.
Comparative toxicity
Direct comparison
Safety results from Belenkaya et al, 2005
Trial ID |
Weight gain |
EPS |
Somnolence and dry mouth |
---|---|---|---|
Belenkaya et al, 2005 |
13% |
33% |
NR |
Ionescu et al, 2004 |
EPS = Extrapyramidal side-effects
Ionescu et al, 2004 does not present any comparative toxicity results apart from stating
“a significant higher percentage of olanzapine treated patients required adjuvant
medication for Extra pyramidal symptoms (EPS) or had EPS”.
Indirect comparison
Change in Simpson–Angus Scale (SARS) scores from baseline
Quetiapine |
Placebo |
||||||
---|---|---|---|---|---|---|---|
n |
Mean |
SD |
n |
Mean |
SD |
||
AZ 104 |
Day 21 |
102 |
-0.8 |
2.66 |
101 |
-0.7 |
2.45 |
AZ 105 |
Day 21 |
107 |
-0.8 |
2.28 |
95 |
-0.5 |
2.65 |
AZ 104 |
Day 84 |
102 |
-0.8 |
2.66 |
101 |
-0.9 |
2.47 |
AZ 105 |
Day 84 |
107 |
-0.8 |
2.28 |
95 |
-0.5 |
2.65 |
Olanzapine |
Placebo |
||||||
Tohen et al, 1999 |
Day 21 |
68 |
-0.15 |
2.12 |
63 |
0.05 |
1.88 |
Tohen et al, 2000 |
Day 28 |
54 |
-0.27 |
1.16 |
56 |
0.13 |
1.61 |
Change in Barnes Akathisia Scale (BARS) scores from baseline
Quetiapine |
Placebo |
||||||
---|---|---|---|---|---|---|---|
n |
Mean |
SD |
n |
Mean |
SD |
||
AZ 104 |
Day 21 |
102 |
-0.2 |
0.74 |
101 |
-0.1 |
0.73 |
AZ 105 |
Day 21 |
107 |
0 |
0.39 |
95 |
0 |
0.58 |
AZ 104 |
Day 84 |
102 |
-0.2 |
0.71 |
101 |
-0.2 |
0.64 |
AZ 105 |
Day 84 |
107 |
0 |
0.37 |
95 |
0 |
0.55 |
Olanzapine |
Placebo |
||||||
Tohen et al, 1999 |
Day 21 |
70 |
-0.17 |
0.8 |
66 |
-0.11 |
0.64 |
Tohen et al, 2000 |
Day 28 |
54 |
-0.40 |
0.83 |
56 |
-0.16 |
0.76 |
In regard to the olanzapine trials, olanzapine-treated patients showed an improvement
in parkinsonism (SARS) and akathisia (BARS) from baseline to end point, whereas placebo-treated
patients experienced a worsening in Parkinsonism and an improvement in akathisia.
However, these differences are not statistically significant. In comparison, both
the active treatment and placebo arms in the quetiapine trials demonstrated improvement
in Parkinsonism and akathisia.
Mean weight gain/loss from baseline across the randomised trials
Trial ID |
Quetiapine |
Placebo |
Olanzapine |
Difference vs placebo |
---|---|---|---|---|
Day 21 |
||||
AZ 104 |
0.3kg 2.23 |
-0.1kg 1.11 |
0.4kg, p NR |
|
AZ 105 |
1.1kg 2.06 |
-0.4kg 1.95 |
1.5kg, p NR |
|
Tohen et al, 1999 |
-0.44 kg 2.35 |
1.65 kg 2.54 |
2.09kg, p<0.001 |
|
Day 28 |
||||
Tohen et al, 2000 |
0.45kg 2.30 |
2.1kg 2.80 |
1.65kg, p=0.002 |
|
Day 84 |
||||
AZ 104 |
0.9kg 3.55 |
-0.3kg 2.55 |
1.2kg, p NR |
|
AZ 105 |
2.6kg 4.23 |
-0.1 3.34 |
2.7kg, p NR |
|
Pooled result (random effects) |
||||
Chi-square for heterogeneity: P= |
The results at Day 21/28 indicate that olanzapine-treated patients had a greater mean weight gain than quetiapine-treated patients.
9. Clinical Claim
The submission claimed that quetiapine is no worse than olanzapine in terms of effectiveness
and toxicity.
For PBACs view of this claim See Recommendations and Reasons
10. Economic Analysis
The submission presented a cost-minimisation analysis. The PBAC noted the trial data indicated that the equi-effective doses for the treatment of bipolar disorder are quetiapine 29 mg (base) for 42 days and olanzapine 1 mg for 42 days, and that the equi-effective doses for the treatment of bipolar disorder for risperidone and olanzapine are 3.75 mg per day and 10.4 mg per day. These values indicated the equi-effective doses for the treatment of bipolar disorder are approximately quetiapine 300 mg (base) per day and risperidone 3.75 mg per day.
11. Estimated PBS Usage and Financial Implications
The submission estimated the likely number of packs dispensed/year to be in the range
100,000 – 200,000 in Year 5.
The submission estimated the listing would be associated with the financial savings/year
to the PBS (excluding co-payments) minus any savings in use of other drugs to be less
than $1 million in Year 5 of listing.
12. Recommendation and Reasons
The PBAC recommended the listing of quetiapine for the treatment, as monotherapy,
of an acute episode of mania associated with bipolar 1 disorder on a cost-minimisation
basis compared with olanzapine. The PBAC considered quetiapine to be no worse than
olanzapine in terms of safety and efficacy. However, the Committee had some remaining
doubts about the evidence provided to support the claim, given that the direct randomised
trials were small and used an open label design, while the trials in the indirect
comparison differed significantly in aspects of trial design and patient characteristics.
Recommendation
QUETIAPINE FUMARATE, tablet, 25 mg, 100 mg, 200 mg and 300 mg (base)
Restriction: Authority required
Monotherapy, for up to 6 months, of an episode of acute mania associated with bipolar
1 disorder.
Maximum Quantity: 60 (25mg, 200mg, 300 mg), 90 (100 mg)
Number of repeats: 5 (all strengths)
13. Context for Decision
The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.
14. Sponsor’s Comment
AstraZeneca Australia welcomes the PBAC recommendation for Seroquel to be listed on
the PBS, to provide access to an additional treatment option for patients diagnosed
with acute mania associated with bipolar I disorder.